Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours – appraisal consultation document

In this DRAFT guidance, avapritinib is not recommended as cost-effectiveness estimates are higher than the range normally considered a cost-effective use of NHS resources and avapritinib does not meet the criteria to be included in the Cancer Drugs Fund.

Source:

National Institute for Health and Care Excellence